Ginkgo Bioworks

Public

Synthetic biology company that builds an automated platform for programming cells, enabling customers across pharmaceuticals, agriculture, and industrial chemicals to harness the power of biology.

Founders Jason Kelly, Reshma Shetty, Tom Knight, Barry Canton, Austin Che
CEO Jason Kelly

Company

Founded
2008
Headquarters
Boston, US
Employees
501-1000

Financials

Total Funding
$720M
Revenue (ARR)
$100M-$500M

Public Market

Exchange
NYSE
Ticker
DNA
IPO Date
Sep 17, 2021
Sectors
Artificial Intelligence Biotech
www.ginkgo.bio Twitter Blog

Funding History

7 rounds
IPO Sep 17, 2021
NYSE: DNA
Series E Sep 19, 2019
$290M
Valuation: $4.0B
T. Rowe Price (Lead) Viking Global Investors Cascade Investment General Atlantic
Series D Dec 14, 2017
$275M
Valuation: $1.0B
Viking Global Investors YC Continuity Cascade Investment General Atlantic
Series C Jun 8, 2016
$100M
Valuation: $525M
YC Continuity Senator Investment Group Cascade Investment Baillie Gifford Viking Global Investors Allen & Company
Series B Jul 23, 2015
$45M
Valuation: $200M
Viking Global Investors (Lead) OS Fund Y Combinator Felicis Ventures
Series A Mar 18, 2015
$9M
OS Fund Felicis Ventures DCVC iGlobe Partners Vast Ventures
Seed Jul 16, 2014
$1M
Y Combinator (Lead)
Grant Jun 1, 2009
$100K

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.